ANZUPGO (Delgocitinib) Patent Expiration, LOE Window & CMS Spending

ANZUPGO (Delgocitinib) by Leo As: FDA Orange Book core substance LOE 2031-09-19, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $1,986 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLeo As
FDA Application & PathwayN219155 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-09-19
Last Listed Patent or Exclusivity Date2031-09-19
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,986 intro WAC)